Aurinia Pharmaceuticals Inc (AUPH)

$4.81

-0.1

(-2.04%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Aurinia Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 54.51M → 45.09M (in $), with an average decrease of 17.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.49M → -26.87M (in $), with an average decrease of 58.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 102.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 305.3%

Performance

  • $4.71
    $4.96
    $4.81
    downward going graph

    2.08%

    Downside

    Day's Volatility :4.94%

    Upside

    2.93%

    downward going graph
  • $4.81
    $12.43
    $4.81
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :61.3%

    Upside

    61.3%

    downward going graph

Returns

PeriodAurinia Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-37.69%
-0.7%
0.0%
6 Months
-35.98%
6.6%
0.0%
1 Year
-55.36%
3.7%
-1.5%
3 Years
-58.95%
14.0%
-21.8%

Highlights

Market Capitalization
723.1M
Book Value
$2.63
Earnings Per Share (EPS)
-0.54
PEG Ratio
0.0
Wall Street Target Price
11.29
Profit Margin
-44.45%
Operating Margin TTM
-52.72%
Return On Assets TTM
-10.52%
Return On Equity TTM
-19.92%
Revenue TTM
175.5M
Revenue Per Share TTM
1.23
Quarterly Revenue Growth YOY
58.599999999999994%
Gross Profit TTM
83.4M
EBITDA
-74.1M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.05
EPS Estimate Next Year
0.39
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Aurinia Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 134.72%

Current $4.81
Target $11.29

Company Financials

FY18Y/Y Change
Revenue
463.0K
↑ 10.24%
Net Income
-64.1M
↓ 9.42%
Net Profit Margin
-13.8K%
↑ 3006.43%
FY19Y/Y Change
Revenue
318.0K
↓ 31.32%
Net Income
-123.8M
↑ 93.15%
Net Profit Margin
-38.9K%
↓ 25096.47%
FY20Y/Y Change
Revenue
50.1M
↑ 15660.38%
Net Income
-102.7M
↓ 17.09%
Net Profit Margin
-204.88%
↑ 38740.4%
FY21Y/Y Change
Revenue
45.6M
↓ 9.0%
Net Income
-181.0M
↑ 76.24%
Net Profit Margin
-396.81%
↓ 191.93%
FY22Y/Y Change
Revenue
134.0M
↑ 193.89%
Net Income
-108.2M
↓ 40.22%
Net Profit Margin
-80.71%
↑ 316.1%
FY23Y/Y Change
Revenue
175.5M
↑ 30.95%
Net Income
-78.0M
↓ 27.88%
Net Profit Margin
-44.45%
↑ 36.26%
Q3 FY22Q/Q Change
Revenue
55.8M
↑ 97.86%
Net Income
-9.0M
↓ 74.69%
Net Profit Margin
-16.12%
↑ 109.86%
Q4 FY22Q/Q Change
Revenue
28.4M
↓ 49.02%
Net Income
-26.0M
↑ 189.75%
Net Profit Margin
-91.6%
↓ 75.48%
Q1 FY23Q/Q Change
Revenue
34.4M
↑ 21.01%
Net Income
-26.2M
↑ 0.61%
Net Profit Margin
-76.16%
↑ 15.44%
Q2 FY23Q/Q Change
Revenue
41.5M
↑ 20.59%
Net Income
-11.5M
↓ 56.15%
Net Profit Margin
-27.7%
↑ 48.46%
Q3 FY23Q/Q Change
Revenue
54.5M
↑ 31.38%
Net Income
-13.4M
↑ 17.01%
Net Profit Margin
-24.67%
↑ 3.03%
Q4 FY23Q/Q Change
Revenue
45.1M
↓ 17.28%
Net Income
-26.9M
↑ 99.86%
Net Profit Margin
-59.6%
↓ 34.93%
FY18Y/Y Change
Total Assets
145.9M
↓ 23.17%
Total Liabilities
33.3M
↑ 38.1%
FY19Y/Y Change
Total Assets
326.7M
↑ 123.97%
Total Liabilities
53.2M
↑ 59.72%
FY20Y/Y Change
Total Assets
463.7M
↑ 41.93%
Total Liabilities
55.9M
↑ 5.16%
FY21Y/Y Change
Total Assets
543.4M
↑ 17.19%
Total Liabilities
64.3M
↑ 14.96%
FY22Y/Y Change
Total Assets
470.9M
↓ 13.34%
Total Liabilities
65.4M
↑ 1.79%
FY23Y/Y Change
Total Assets
548.1M
↑ 16.4%
Total Liabilities
170.1M
↑ 160.0%
Q3 FY22Q/Q Change
Total Assets
488.3M
↑ 1.27%
Total Liabilities
64.9M
↑ 11.11%
Q4 FY22Q/Q Change
Total Assets
470.9M
↓ 3.57%
Total Liabilities
65.4M
↑ 0.86%
Q1 FY23Q/Q Change
Total Assets
451.8M
↓ 4.06%
Total Liabilities
61.4M
↓ 6.22%
Q2 FY23Q/Q Change
Total Assets
548.9M
↑ 21.5%
Total Liabilities
156.6M
↑ 155.26%
Q3 FY23Q/Q Change
Total Assets
555.0M
↑ 1.11%
Total Liabilities
163.1M
↑ 4.17%
Q4 FY23Q/Q Change
Total Assets
548.1M
↓ 1.25%
Total Liabilities
170.1M
↑ 4.27%
FY18Y/Y Change
Operating Cash Flow
-51.6M
↑ 25.36%
Investing Cash Flow
-65.0K
↓ 99.19%
Financing Cash Flow
4.0M
↓ 97.71%
FY19Y/Y Change
Operating Cash Flow
-63.5M
↑ 22.95%
Investing Cash Flow
7.8M
↓ 12073.85%
Financing Cash Flow
243.7M
↑ 5971.95%
FY20Y/Y Change
Operating Cash Flow
-69.9M
↑ 10.09%
Investing Cash Flow
-158.2M
↓ 2132.46%
Financing Cash Flow
194.4M
↓ 20.25%
FY21Y/Y Change
Operating Cash Flow
-157.7M
↑ 125.73%
Investing Cash Flow
-103.9M
↓ 34.34%
Financing Cash Flow
221.1M
↑ 13.76%
FY22Y/Y Change
Operating Cash Flow
-79.5M
↓ 49.57%
Investing Cash Flow
-60.6M
↓ 41.63%
Financing Cash Flow
2.4M
↓ 98.9%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.4M
↓ 44.88%
Investing Cash Flow
-50.2M
↓ 210.08%
Financing Cash Flow
-23.9K
↓ 101.78%
Q4 FY22Q/Q Change
Operating Cash Flow
10.5M
↓ 168.02%
Investing Cash Flow
-3.0M
↓ 93.99%
Financing Cash Flow
688.0K
↓ 2982.04%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.7M
↓ 403.06%
Investing Cash Flow
24.9M
↓ 923.72%
Financing Cash Flow
1.6M
↑ 138.23%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.8M
↓ 91.08%
Investing Cash Flow
-5.6M
↓ 122.56%
Financing Cash Flow
1.1M
↓ 30.45%

Technicals Summary

Sell

Neutral

Buy

Aurinia Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
-3.54%
-35.98%
-55.36%
-58.95%
-22.19%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
NA
NA
0.0
-0.05
-0.2
-0.11
NA
2.63
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
Buy
$723.1M
-22.19%
NA
-44.45%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Armistice Capital, LLC

    6.59%
  • BlackRock Inc

    6.17%
  • Goldman Sachs Group Inc

    2.83%
  • NEA Management Company, LLC

    2.75%
  • State Street Corporation

    1.87%
  • Nuveen Asset Management, LLC

    1.63%

Corporate Announcements

  • Aurinia Pharmaceuticals Inc Earnings

    Aurinia Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Organization
Aurinia Pharmaceuticals Inc
Employees
300
CEO
Mr. Peter S. Greenleaf M.B.A.
Industry
Health Technology

FAQs